LENZ Therapeutics (LENZ) Payables (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Payables data on file, last reported at $10.9 million in Q1 2026.

• Payables for Q1 2026 came in at $10.9 million, up 198.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.9 million (up 198.52% YoY), and the FY2025 annual result was $4.2 million, down 2.11% from the prior year.
• Payables improved to $10.9 million in Q1 2026 per LENZ's latest filing, from $4.2 million in the prior quarter.
• Over five years, Payables peaked at $10.9 million in Q1 2026 and troughed at $2.0 million in Q1 2023.
• A 5-year average of $4.2 million and a median of $3.8 million in 2023 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables jumped 257.98% in 2024, then sank 48.66% in 2025.
• A 5-year view of Payables shows it stood at $2.6 million in 2022, then soared by 118.98% to $5.7 million in 2023, then decreased by 25.46% to $4.3 million in 2024, then retreated by 2.11% to $4.2 million in 2025, then surged by 162.28% to $10.9 million in 2026.
• Business Quant data shows LENZ's Payables at $10.9 million in Q1 2026, $4.2 million in Q4 2025, and $4.3 million in Q3 2025.